SuperGen Acquires European Marketing Authorizations for Nipent(R) from Pfizer

DUBLIN, Calif., Feb. 24 /PRNewswire-FirstCall/-- SuperGen Inc. (Nasdaq: SUPG -) today announced that it has acquired European marketing authorizations to the anticancer compound Nipent® (pentostatin for injection) from Pfizer Inc. and plans to retain the exclusive European distributor for Nipent for the near term. Nipent is currently approved as a single-agent treatment for patients with hairy cell leukemia and under investigational study for a number of hematological malignancies. Terms of the transaction were not disclosed.

In 1996, SuperGen purchased domestic distribution and marketing rights to Nipent from the Warner-Lambert Company, which was later acquired by Pfizer.

"As a result of this transaction with Pfizer, we are now able to drive Nipent commercialization globally, outside of Japan," said Edward Jacobs, Chief Operating Officer of SuperGen. "Although our European affiliate, EuroGen Pharmaceuticals Ltd., has been in existence for several years, the acquisition of these rights marks the true beginning of our commercial activity in Europe. We anticipate revenue to be generated by EuroGen products in 2004."

SuperGen is currently conducting clinical studies using Nipent as a treatment for several hematological malignancies, including graft-versus-host disease (an often-fatal syndrome wherein immune cells from the transplant donor reject the recipient's normal tissue following an allogeneic transplant), non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapeutic anticancer products. The company's website can be reached at www.supergen.com.

This press release contains "forward-looking" statements within the meaning of section 21A of the Securities Act of 1933, as amended, and section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created thereby. Such forward-looking statements include statements related to our expectations regarding Nipent as a single agent and in combination with other chemotherapeutic drugs in the treatment of various hematological conditions. The success of such product could differ materially from those discussed in the forward-looking statements as a result of known and unknown risk factors and uncertainties. Such factors include, but are not limited to: risks and uncertainties related to initiating, conducting and completing larger clinical trials in patients, reduced intensity of allogeneic bone marrow transplant patients with MDS, whether Nipent will demonstrate any clinical benefit in any future study of these patients, and whether the company will submit or receive regulatory approval for Nipent for this indication. References made to the discussion of the risk factors are detailed in the company's filing with the Securities and Exchange Commission including the report on Form 10-Q for the quarter ended September 30, 2003. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update or revise the information contained in any such forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
Tim Enns, Vice President, Investor Relations & Business Development,
SuperGen Inc., 800-353-1075, ext. 111